Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
Top Page
Tvardi Therapeutics
(NASDAQ:TVRD)
Select Model
Select Model
Rating:41Neutral
Price Target:
$3.00
▲(3.45% Upside)
Action:ReiteratedDate:04/02/26
The score is primarily held down by weak financial performance (zero revenue, ongoing losses, and persistent cash burn) and bearish technicals (price below key moving averages with negative MACD). Valuation offers limited support given losses and no dividend, while recent clinical/pipeline updates add incremental risk due to mixed/negative trial readouts and execution challenges.
Positive Factors
Low leverage on balance sheet
Very low reported debt relative to equity materially reduces near-term refinancing and interest burden risks. For a clinical-stage biotech this structural conservatism increases financial optionality over the next 2–6 months, lowering bankruptcy probability and enabling focus on clinical milestones without heavy fixed-cost pressure.
Negative Factors
Zero revenue and collapsed commercial base
The structural loss of revenue eliminates internal product cash generation and removes self-funding capacity. Over 2–6 months this means reliance on cash reserves or financing for operations, reduces strategic flexibility, and magnifies the impact of any clinical setbacks on corporate survival and dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage on balance sheet
Very low reported debt relative to equity materially reduces near-term refinancing and interest burden risks. For a clinical-stage biotech this structural conservatism increases financial optionality over the next 2–6 months, lowering bankruptcy probability and enabling focus on clinical milestones without heavy fixed-cost pressure.
Read all positive factors
Tvardi Therapeutics (TVRD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.21M
Dividend YieldN/A
Average Volume (3M)401.55K
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue Growth-53.67%
EPS Growth86.75%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.78
Shares Outstanding9,381,344
10 Day Avg. Volume1,070,842
30 Day Avg. Volume401,545
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue3.11
Enterprise Value/Gross Profit3.17
Enterprise Value/Ebitda-0.33
Forecast
1Y Price Target
$8.33Price Target Upside187.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.06
Revenue Forecast (FY)N/A
Tvardi Therapeutics Business Overview & Revenue Model
Company Description
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently...
How the Company Makes Money
null...
Tvardi Therapeutics Earnings Call Summary
Earnings Call Date:Mar 04, 2024
(Q4-2023)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted a strategic focus on a promising NP program with potential for significant clinical and commercial success. However, challenges with KORSUVA revenue and increased R&D expenses were notable concerns.Positive Updates
Focus on Notalgia Paresthetica
Cara Therapeutics has prioritized its program focusing on oral difelikefalin for notalgia paresthetica (NP), a chronic neuropathic condition with a significant unmet need. This strategic focus extends their cash runway into 2026.
Negative Updates
Challenges with KORSUVA Revenue
Despite demand growth, unfavorable reimbursement changes are expected to significantly restrict access to KORSUVA, leading to minimal revenue contributions.
Read all updates
Q4-2023 Updates
Positive
Negative
Focus on Notalgia Paresthetica
Cara Therapeutics has prioritized its program focusing on oral difelikefalin for notalgia paresthetica (NP), a chronic neuropathic condition with a significant unmet need. This strategic focus extends their cash runway into 2026.
Read all positive updates
Company Guidance
In the earnings call for Cara Therapeutics, the company provided guidance focused on the development of oral difelikefalin for notalgia paresthetica (NP), prioritizing this program to extend their cash runway into 2026. They reported significant demand growth for KORSUVA injection, with a 22% increase in vial shipments in Q4 2023, although future revenue from KORSUVA is not expected to be substantial due to reimbursement changes. The company highlighted that 34 million U.S. adults suffer from chronic pruritus, with 650,000 diagnosed NP patients, noting the lack of approved therapies and the significant unmet need for effective treatment. The Phase II/III COURAGE I study for NP has completed enrollment ahead of schedule, with top-line results anticipated in Q3 2024. Financially, Cara reported $3 million in revenue for Q4 2023 and ended the year with $1.8 million in cash, cash equivalents, and marketable securities, after using $92.1 million in operating activities and securing $36.5 million from a financing transaction.Tvardi Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
43
Neutral
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 7.14M | 20.97M | 41.87M | 23.03M |
| Gross Profit | 0.00 | 6.33M | 14.54M | 34.35M | 21.47M |
| EBITDA | -26.65M | -62.60M | -117.65M | -83.80M | -86.89M |
| Net Income | -18.21M | -70.87M | -118.51M | -85.47M | -88.44M |
Balance Sheet | |||||
| Total Assets | 32.07M | 43.83M | 27.00M | 45.10M | 247.06M |
| Cash, Cash Equivalents and Short-Term Investments | 30.81M | 37.90M | 22.92M | 43.74M | 167.03M |
| Total Debt | 201.00K | 44.45M | 368.00K | 2.37M | 3.67M |
| Total Liabilities | 11.13M | 48.42M | 89.06M | 90.15M | 19.53M |
| Stockholders Equity | 20.95M | -4.59M | -62.06M | -45.05M | 227.52M |
Cash Flow | |||||
| Free Cash Flow | -23.50M | -61.96M | -21.04M | -17.92M | -60.13M |
| Operating Cash Flow | -23.50M | -60.92M | -21.04M | -17.87M | -60.09M |
| Investing Cash Flow | -10.08M | 48.74M | 22.47M | -22.00M | -4.75M |
| Financing Cash Flow | 22.70M | -3.60M | 2.00K | 4.00K | 46.61M |
Tvardi Therapeutics Technical Analysis
Negative
2.90
Price Trends
3.61
Negative
3.91
Negative
13.78
Negative
Market Momentum
-0.23
Positive
33.55
Neutral
33.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVRD, the sentiment is Negative. The current price of 2.9 is below the 20-day moving average (MA) of 3.30, below the 50-day MA of 3.61, and below the 200-day MA of 13.78, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 33.55 is Neutral, neither overbought nor oversold. The STOCH value of 33.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TVRD.
Tvardi Therapeutics Risk Analysis
Tvardi Therapeutics disclosed 88 risk factors in its most recent earnings report. Tvardi Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tvardi Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $49.02M | 5.20 | -165.19% | ― | -25.51% | 49.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $49.47M | -1.22 | -28.16% | ― | -55.88% | 6.14% | |
41 Neutral | $27.21M | -1.38 | -135.79% | ― | -53.67% | 86.75% | |
40 Underperform | $32.94M | -1.74 | 774.80% | ― | -8.16% | 22.44% |
* Healthcare Sector Average
TVRD
Tvardi Therapeutics
2.90
-13.75
-82.58%
PSTV
Plus Therapeutics
4.80
-11.19
-69.98%
CUE
Cue Biopharma
0.50
-0.29
-36.66%
ALGS
Aligos Therapeutics
8.00
3.39
73.43%
GNTA
Genenta Science SpA Sponsored ADR
0.67
-3.12
-82.35%
ANL
Adlai Nortye Ltd. Sponsored ADR
11.16
9.08
436.54%
Tvardi Therapeutics Corporate Events
Regulatory Filings and ComplianceShareholder Meetings
Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting
Neutral
Mar 6, 2026
Tvardi Therapeutics has scheduled its 2026 Annual Meeting of Stockholders for June 9, 2026, and set March 16, 2026 as the deadline for shareholder proposals to be considered for inclusion in its proxy materials under SEC Rule 14a-8. Under the comp...
Business Operations and StrategyProduct-Related Announcements
Tvardi Therapeutics updates STAT3 fibrosis-focused clinical pipeline
Negative
Jan 16, 2026
In January 2026, Tvardi Therapeutics provided an overview of its clinical pipeline and recent progress in targeting STAT3 for fibrosis-driven diseases, highlighting TTI-101 and TTI-109 as key assets. The company reported that topline data from the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.